Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Controlled Clinical Trial
. 2017 Mar;193(3):192-199.
doi: 10.1007/s00066-016-1070-0. Epub 2016 Nov 1.

Fractionated vs. single-fraction stereotactic radiotherapy in patients with vestibular schwannoma : Hearing preservation and patients' self-reported outcome based on an established questionnaire

Kerstin A Kessel  1   2 , Hanna Fischer  3   4 , Marco M E Vogel  3   4 , Markus Oechsner  3 , Henning Bier  5 , Bernhard Meyer  6 , Stephanie E Combs  3   4
Affiliations
Controlled Clinical Trial

Fractionated vs. single-fraction stereotactic radiotherapy in patients with vestibular schwannoma : Hearing preservation and patients' self-reported outcome based on an established questionnaire

Kerstin A Kessel et al. Strahlenther Onkol. 2017 Mar.

Erratum in

Abstract

Background: Stereotactic radiotherapy (RT) has been established as a valid treatment alternative in patients with vestibular schwannoma (VS). There is ongoing controversy regarding the optimal fractionation. Hearing preservation may be the primary goal for patients with VS, followed by maintenance of quality of life (QoL).

Methods: From 2002 to 2015, 184 patients with VS were treated with radiosurgery (RS) or fractionated stereotactic radiotherapy (FSRT). A survey on current symptoms and QoL was conducted between February and June 2016.

Results: Median follow-up after RT was 7.5 years (range 0-14.4 years). Mean overall survival (OS) after RT was 31.1 years, with 94 and 87% survival at 5 and 10 years, respectively [corrected]. Mean progression-free survival (PFS) was 13.3 years, with 5‑ and 10-year PFS of 92%. Hearing could be preserved in RS patients for a median of 36.3 months (range 2.3-13.7 years). Hearing worsened in 17 (30%) cases. Median hearing preservation for FSRT was 48.7 months (range 0.0-13.8 years); 29 (23%) showed hearing deterioration. The difference in hearing preservation was not significant between RS and FSRT (p = 0.3). A total of 123/162 patients participated in the patient survey (return rate 76%). The results correlate well with the information documented in the patient files for tinnitus and facial and trigeminal nerve toxicity. Significant differences appeared regarding hearing impairment, gait uncertainty, and imbalance.

Conclusion: These data confirm that RS and FSRT are comparable in terms of local control for VS. RS should be reserved for smaller lesions, while FSRT can be offered independently of tumor size. Patient self-reported outcome during follow-up is of high value. The established questionnaire could be validated in the independent cohort.

Keywords: Patient self-reported outcome; Quality of life; Questionnaires; Survial; Toxicity.

PubMed Disclaimer

References

    1. J Neurol Surg B Skull Base. 2016 Jun;77(3):212-8 - PubMed
    1. Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):193-200 - PubMed
    1. World Neurosurg. 2015 Aug;84(2):283-291.e1 - PubMed
    1. Radiother Oncol. 2013 Feb;106(2):175-80 - PubMed
    1. J Neurosurg. 2013 Mar;118(3):557-65 - PubMed

Publication types

MeSH terms

LinkOut - more resources